201 related articles for article (PubMed ID: 16622680)
1. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.
Méndez R; Ruiz-Cabello F; Rodríguez T; Del Campo A; Paschen A; Schadendorf D; Garrido F
Cancer Immunol Immunother; 2007 Jan; 56(1):88-94. PubMed ID: 16622680
[TBL] [Abstract][Full Text] [Related]
2. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.
Cabrera T; Lara E; Romero JM; Maleno I; Real LM; Ruiz-Cabello F; Valero P; Camacho FM; Garrido F
Cancer Immunol Immunother; 2007 May; 56(5):709-17. PubMed ID: 16960691
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.
Carretero R; Romero JM; Ruiz-Cabello F; Maleno I; Rodriguez F; Camacho FM; Real LM; Garrido F; Cabrera T
Immunogenetics; 2008 Aug; 60(8):439-47. PubMed ID: 18545995
[TBL] [Abstract][Full Text] [Related]
4. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient.
Kovalcsik E; John J; Turner M; Birchall L; Sage D; Whittle R; Dalgleish A; Pandha H
Melanoma Res; 2004 Dec; 14(6):463-71. PubMed ID: 15577316
[TBL] [Abstract][Full Text] [Related]
6. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
[TBL] [Abstract][Full Text] [Related]
7. Genetic evolution of T-cell resistance in the course of melanoma progression.
Sucker A; Zhao F; Real B; Heeke C; Bielefeld N; Maβen S; Horn S; Moll I; Maltaner R; Horn PA; Schilling B; Sabbatino F; Lennerz V; Kloor M; Ferrone S; Schadendorf D; Falk CS; Griewank K; Paschen A
Clin Cancer Res; 2014 Dec; 20(24):6593-604. PubMed ID: 25294904
[TBL] [Abstract][Full Text] [Related]
8. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
9. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
10. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
Paschen A; Méndez RM; Jimenez P; Sucker A; Ruiz-Cabello F; Song M; Garrido F; Schadendorf D
Int J Cancer; 2003 Mar; 103(6):759-67. PubMed ID: 12516095
[TBL] [Abstract][Full Text] [Related]
11. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
12. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.
Murphy GF; Radu A; Kaminer M; Berd D
J Invest Dermatol; 1993 Mar; 100(3):335S-341S. PubMed ID: 8440919
[TBL] [Abstract][Full Text] [Related]
13. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
14. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Gil-Julio H; Perea F; Rodriguez-Nicolas A; Cozar JM; González-Ramirez AR; Concha A; Garrido F; Aptsiauri N; Ruiz-Cabello F
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298868
[TBL] [Abstract][Full Text] [Related]
15. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA
Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714
[TBL] [Abstract][Full Text] [Related]
16. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
[TBL] [Abstract][Full Text] [Related]
17. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-melanoma interaction: role of surface molecules.
Becker JC; Bröcker EB
Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
20. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
